Stock Events

Stock Events

XORTX Therapeutics 

$0.4
36
-$0.02-5.66% Today

Statistics

Day High
0.46
Day Low
0.37
52W High
1.41
52W Low
0.35
Volume
73,978
Avg. Volume
144,339
Mkt Cap
2.08M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

14MayExpected
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.5
-0.31
-0.13
0.06
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-6.63MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow XRTX. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals is involved in developing treatments for cystic fibrosis and other diseases, potentially overlapping with XORTX's focus on kidney diseases and conditions that could have similar treatment approaches.
Aurinia Pharmaceuticals
AUPH
Mkt Cap1.73B
Aurinia Pharmaceuticals focuses on the development of therapies for autoimmune diseases, including lupus nephritis, which could compete with XORTX's kidney-focused therapies.
Akebia Therapeutics
AKBA
Mkt Cap585.97M
Akebia Therapeutics works on treatments for kidney disease and anemia, areas that overlap with XORTX's therapeutic focus, making them direct competitors.
Ardelyx
ARDX
Mkt Cap1.47B
Ardelyx focuses on kidney and cardiovascular diseases, offering treatments that could compete with XORTX's products for similar indications.
Trevena
TRVN
Mkt Cap10,365
Trevena develops therapies for central nervous system disorders but has potential overlap in treatment methodologies that could be applied to conditions XORTX targets.
Outlook Therapeutics
OTLK
Mkt Cap55.97M
Outlook Therapeutics is focused on ocular diseases but represents the broader competition in the biopharmaceutical sector, competing for investment and resources.

About

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat gout and progressive kidney disease. Its drug development programs include XRx-026, which is in the third phase for the treatment of gout; XRx-008, which is in the second phase to treat autosomal dominant polycystic kidney disease; XRx-101, which is in the second phase to treat acute kidney injury associated with respiratory virus infection; and XRX-225, which is in the preclinical stage for the treatment of type 2 diabetic nephropathy. It has a license agreement with the University of Florida Research Foundation, Inc. for the use of uric acid lowering agent to treat insulin resistance. The company is based in Calgary, Canada.
Show more...
CEO
Dr. Allen Warren Davidoff Ph.D.
Employees
2
Country
CA
ISIN
CA98420Q3061

Listings

F
DE
ANU.F
F
DE
ANUA.F
V
CA
XRTX.V
XNAS
US
XRTX

0 Comments

Share your thoughts

FAQ

What is XORTX Therapeutics stock price today?▼
The current price of XRTX is $0.4 USD — it has decreased by -5.66% in the past 24 hours. Watch XORTX Therapeutics stock price performance more closely on the chart.
What is XORTX Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange XORTX Therapeutics stocks are traded under the ticker XRTX.
Is XORTX Therapeutics stock price growing?▼
XRTX stock has risen by +16.41% compared to the previous week, the month change is a -4.38% fall, over the last year XORTX Therapeutics has showed a -58.17% decrease.
What is XORTX Therapeutics market cap?▼
Today XORTX Therapeutics has the market capitalization of 2.08M
When is the next XORTX Therapeutics earnings date?▼
XORTX Therapeutics is going to release the next earnings report on May 14, 2026.
What were XORTX Therapeutics earnings last quarter?▼
XRTX earnings for the last quarter are -0.05 USD per share, whereas the estimation was -0.17 USD resulting in a +70.08% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is XORTX Therapeutics revenue for the last year?▼
XORTX Therapeutics revenue for the last year amounts to 0 USD.
What is XORTX Therapeutics net income for the last year?▼
XRTX net income for the last year is -6.63M USD.
How many employees does XORTX Therapeutics have?▼
As of April 02, 2026, the company has 2 employees.
In which sector is XORTX Therapeutics located?▼
XORTX Therapeutics operates in the Health Care sector.
When did XORTX Therapeutics complete a stock split?▼
The last stock split for XORTX Therapeutics was on November 14, 2023 with a ratio of 1:9.
Where is XORTX Therapeutics headquartered?▼
XORTX Therapeutics is headquartered in Calgary, CA.